7th Apr 2017 15:56
7 April 2017
AIM: REDX
REDX PHARMA PLC
("Redx" or "the Company")
Notice of Annual General Meeting
Redx Pharma, the research and development company focused on cancer, immunology and infection, announces that its Annual General Meeting will be held at 9.30am on 20 April 2017 at Redx Pharma Plc, Mereside, Alderley Park, Macclesfield SK10 4TG, UK.
Following the announcement of preliminary results for the financial year ended 30 September 2016 on 21 March, the Company announces that the Annual Report and Accounts and notice of Annual General Meeting have now been posted to shareholders. The Annual Report and Accounts is also available to view on Redx's website at www.redxpharma.com.
For further information, please contact:
Redx Pharma Plc |
|
Neil Murray, Chief Executive Officer | T: +44 1625 469 900 |
Karl Hård, Head of Investor Relations & Corporate Communications | T: +44 7491 651 406 |
Cantor Fitzgerald Europe (Nomad & Broker) |
T: +44 20 7894 7000 |
Phil Davies/ Michael Reynolds |
|
|
|
WG Partners LLP (Joint Broker) | T: +44 20 3705 9330 |
Claes Spång/ Chris Lee/ David Wilson |
|
Consilium Strategic Communications | T: +44 20 3709 5700 |
Amber Fennell/ Matthew Neal/ Melissa Gardiner |
|
About Redx Pharma Plc
Company website: www.redxpharma.com
Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, immunology and infection providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a broad portfolio of proprietary drug programs.
Related Shares:
REDX.L